Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo de estudio
Tipo del documento
Intervalo de año de publicación
1.
Eur J Pharm Biopharm ; 132: 62-69, 2018 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-30118752

RESUMEN

Vaccine thermostability is key to successful global immunization programs as it may have a significant impact on the continuous cold-chain maintenance logistics, as well as affect vaccine potency. Modern biological and biophysical techniques were combined to in-depth characterize the thermostability of a formulated rabies virus (RABV) in terms of antigenic and genomic titer, virus particle count and aggregation state. Tunable resistive pulse sensing (TRPS) and nanoparticle tracking analysis (NTA) were used to count virus particles while simultaneously determining their size distribution. RABV antigenicity was assessed by NTA using a monoclonal antibody that recognize a rabies glycoprotein (G protein) conformational epitope, enabling to specifically count antigenic rabies viruses. Agreement between antigenicity results from NTA and conventional method, as ELISA, was demonstrated. Additionally, NTA and ELISA showed mirrored loss of RABV antigenicity during forced degradation studies performed between 5 °C and 45 °C temperature exposure for one month. Concomitant with decreased antigenicity, emergence of RABV particle populations larger than those expected for rabies family viruses was observed, suggesting RABV aggregation induced by thermal stress. Finally, using a kinetic-based modeling approach to explore forced degradation antigenicity data (NTA, ELISA), a two-step model accurately describing antigenicity loss was identified. This model predicted a RABV shelf-life of more than 3 years at 5 °C; significant loss of antigenicity was predicted for samples maintained several months at ambient temperature. This thorough characterization of RABV forced degradation study originally provided a time-temperature mapping of RABV stability.


Asunto(s)
Anticuerpos Monoclonales/administración & dosificación , Vacunas Antirrábicas/inmunología , Virus de la Rabia/inmunología , Virión/inmunología , Anticuerpos Monoclonales/inmunología , Antígenos Virales/inmunología , Estabilidad de Medicamentos , Almacenaje de Medicamentos , Ensayo de Inmunoadsorción Enzimática , Inmunogenicidad Vacunal/inmunología , Nanopartículas , Vacunas Antirrábicas/química , Temperatura , Factores de Tiempo , Potencia de la Vacuna
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA